Top Page
Jinhai International Group Holdings Limited
(2225)
Jinhai International Group Holdings Limited (2225) vs. iShares MSCI Hong Kong ETF (EWH)
Jinhai International Group Holdings Limited Business Overview & Revenue Model
Jinhai International Group Holdings Limited Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 50.24M | 45.64M | 22.28M | 21.90M | 22.47M |
| Gross Profit | 11.48M | 12.03M | 10.12M | 7.73M | 8.85M |
| EBITDA | -16.82M | 1.11M | 3.57M | 5.44M | 2.15M |
| Net Income | -17.96M | -3.14M | 468.00K | -246.21K | 1.26M |
Balance Sheet | |||||
| Total Assets | 58.87M | 62.22M | 40.27M | 33.77M | 39.41M |
| Cash, Cash Equivalents and Short-Term Investments | 14.93M | 26.76M | 26.05M | 25.91M | 25.95M |
| Total Debt | 14.52M | 10.08M | 4.45M | 1.87M | 5.50M |
| Total Liabilities | 26.09M | 24.73M | 15.68M | 9.75M | 13.92M |
| Stockholders Equity | 31.81M | 37.47M | 24.37M | 24.28M | 25.49M |
Cash Flow | |||||
| Free Cash Flow | -4.26M | -3.15M | 3.06M | 2.73M | 7.25M |
| Operating Cash Flow | -3.25M | -1.91M | 4.24M | 3.34M | 7.38M |
| Investing Cash Flow | -9.22M | -6.51M | -1.15M | -2.64M | -6.04M |
| Financing Cash Flow | 2.93M | 13.62M | -3.72M | -4.81M | -4.15M |
Jinhai International Group Holdings Limited Technical Analysis
Jinhai International Group Holdings Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Neutral | 1.12B | 7.35 | 10.36% | 35.44% | 17.49% | 9.67% | |
66 Neutral | 57.00M | 5.65 | 13.97% | ― | -11.47% | 5.00% | |
66 Neutral | 1.99B | 12.92 | 4.36% | ― | -10.48% | 30250.00% | |
54 Neutral | 751.44M | -13.02 | -5.93% | 1.82% | 14.29% | -200.37% | |
54 Neutral | 38.43M | -3.94 | 28.99% | ― | 0.00% | 0.00% | |
43 Neutral | HK$5.82B | ― | -67.70% | ― | -33.94% | -119.13% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
Jinhai International Group Holdings Limited Corporate Events
Jinhai Medical Technology Limited has announced that its board of directors will convene on August 29, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. This meeting will also consider the payment of an interim dividend, which could have implications for shareholders and reflect the company’s financial health and strategic direction.
Jinhai Medical Technology Limited has successfully completed the issuance of 120,000,000 new shares under its general mandate, raising approximately HK$161.0 million in net proceeds. The funds will be used for potential mergers and acquisitions in the healthcare sector, research and development, and general working capital. This strategic move slightly dilutes existing shareholders but positions the company for growth and expansion in its industry.
Jinhai Medical Technology Limited announced the signing of three Subscription Agreements with independent private investors to issue a total of 120,000,000 new shares at a price of HK$1.35 per share. This move, under the General Mandate, represents a strategic effort to raise capital without requiring shareholder approval, potentially impacting the company’s market positioning by increasing its share capital by approximately 2.27%. The subscription price reflects a discount to recent market prices, indicating a strategic decision to attract investment under current market conditions.
Jinhai Medical Technology Limited has announced supplementary information to its 2024 Annual Report, focusing on remedial measures for risk management and internal control systems. The company has implemented enhanced internal control policies, conducted training sessions, hired qualified staff, and sought external advice to ensure compliance with the Listing Rules. Additionally, the company provided updates on its Share Option Scheme, detailing the number of options available at the beginning and end of the financial year.
Jinhai Medical Technology Limited has entered into a five-year cooperation framework agreement with Ningbo Verykind Medical Device Co., Ltd., a subsidiary of David Medical Group, to collaborate on endoscope products for international markets. This partnership aims to enhance product delivery efficiency, cost competitiveness, and global academic influence through resource optimization and international certifications. The agreement is expected to broaden Jinhai’s income stream and align with its development strategy, ultimately benefiting shareholders.
Jinhai Medical Technology Limited announced that all resolutions proposed at its Annual General Meeting (AGM) held on June 25, 2025, were unanimously approved by shareholders. The resolutions included the adoption of financial statements, re-election of directors, authorization of director remuneration, re-appointment of auditors, and granting of mandates for share issuance and repurchase. This unanimous approval reflects strong shareholder confidence in the company’s governance and strategic direction, potentially reinforcing its market position and operational stability.
Jinhai Medical Technology Limited has announced its upcoming annual general meeting scheduled for June 25, 2025, in Shanghai, China. Key agenda items include the adoption of the company’s audited financial statements for 2024, the re-election of several directors, and the re-appointment of ZHONGHUI ANDA CPA Limited as the company’s auditor. Additionally, the meeting will address resolutions related to the issuance of shares, which could impact the company’s capital structure and shareholder value.